Company Name : Dassault Systèmes

Thursday, October 11, 2018 5:20PM IST (11:50AM GMT)
NIMHANS Uses Simulation From Dassault Systèmes in Its Research to Improve Efficacy of Medical Treatment Through Neuromodulation
Bengaluru, Karnataka, India
  • NIMHANS adopts Dassault Systèmes’ SIMULIA applications powered by the 3DEXPERIENCE platform

  • Accurate simulations could potentially help medical professionals forecast challenges and outcomes of treatment procedures for patients with schizophrenia

  • First-of-a-kind deployment announced at Dassault Systèmes’ first ever local edition of its global event Science in the Age of Experience in India

Dassault Systèmes (Euronext Paris: #13065, DSY.PA) announced that National Institute of Mental Health & Neuro Sciences (NIMHANS), the apex center for mental health and neuroscience education in India, has deployed Dassault Systèmes’ SIMULIA applications to predict the efficacy of Transcranial Direct Current Stimulation (tDCS), a non-invasive clinical treatment for schizophrenia patients, virtually before the clinical procedure. The announcement was made at Dassault Systèmes’ first ever local edition of its global event Science in the Age of Experience in India that aims to showcase the company’s simulation applications in transportation, aerospace and life sciences verticals.
 
NIMHANS’s adoption of SIMULIA applications powered by the 3DEXPERIENCE platform is a first-of-its-kind deployment, where psychiatrists at NIMHANS will be able to leverage simulation technology to forecast challenges and outcomes of the treatment procedure for disorders such as schizophrenia. With SIMULIA applications, the team envisages the potential to develop a conceptual non-invasive method for Deep Brain Stimulation.

Dr. G. Venkatasubramanian, MD PhD, Professor of Psychiatry, Head, Department of Clinical Neurosciences at NIMHANS, “Computational modelling and simulation technologies allow mathematical reconstruction of the impact of tDCS in the treatment of several neuropsychiatric disorders. With multiphysics simulation capabilities on the 3DEXPERIENCE platform, under the WISER Neuromodulation Program at the National Institute of Mental Health and Neurosciences, patient-specific finite element models of the brain are used to accurately estimate the likely impact of electrical stimulation for treating the symptoms of schizophrenia, which, in turn can facilitate personalized neuromodulation.”
 
At the announcement, Samson Khaou, Managing Director, India, Dassault Systèmes said, “The biggest challenge faced today by the healthcare sector in India is the absence of a standard procedure to predict the effectiveness of a treatment for various chronic diseases. As the life sciences industry moves towards more ‘personalized healthcare’, custom-made simulations allow for more precise analyses and predictions of human body dynamics. With Dassault Systèmes’ SIMULIA and BIOVIA applications on the 3DEXPERIENCE platform, we aim to bridge this gap by enabling our customers develope new and innovative methods for patients treatment.”
 
Historically, simulation has not played as large a role in life sciences as it has in more traditional engineering industries like automotive or aerospace. In addition, the simulation of human systems and their interaction is considerably more difficult and less evolved than the simulation of metal components. Human tissue response is complex and not easily simulated with simplified models. SIMULIA applications contain a wide variety of materials, procedures and load types to simulate the human body, medical and surgical equipment, and the manner in which the equipment is used.
 
For more information:
 
Dassault Systèmes’ SIMULIA please visit: https://www.3ds.com/products-services/simulia/
Dassault Systèmes’ BIOVIA please visit: https://www.3ds.com/products-services/biovia/
 
Dassault Systèmes’ 3DEXPERIENCE platform, 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions: http://www.3ds.com

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, provides business and people with virtual universes to imagine sustainable innovations. Its world-leading solutions transform the way products are designed, produced, and supported. Dassault Systèmes’ collaborative solutions foster social innovation, expanding possibilities for the virtual world to improve the real world. The group brings value to over 220,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.
 
3DEXPERIENCE, the Compass logo and the 3DS logo, CATIA, SOLIDWORKS, ENOVIA, DELMIA, SIMULIA, GEOVIA, EXALEAD, 3D VIA, BIOVIA, NETVIBES and 3DEXCITE are registered trademarks of Dassault Systèmes or its subsidiaries in the US and/or other countries.
Source: BUSINESS WIRE INDIA

Click here for Media Contact Details

Santanu Bhattacharya,India,Dassault Systèmes,+91 (124) 4577111,+91 (124) 4577111 ,santanu.bhattacharya@3ds.com


More News from Dassault Systèmes

Dassault Systèmes Signs MoU With National Institute of Technology Silchar to Establish NITS Cloud Center for Innovation

06/09/2018 4:30PM

Dassault Systèmes signed a Memorandum of Understanding (MoU) with National Institute of Technology Silchar (NITS) to set up the NITS Cloud Center for Innovation at the institute’s campus in Silchar, Assam. The MoU was ...

Sandhar Adopts Dassault Systèmes 3DEXPERIENCE Platform to Improve End-to-End Product Development

06/09/2018 1:11PM

Dassault Systèmes today announced at the 3DEXPERIENCE Forum 2018 in New Delhi that Sandhar, an Indian engineering company and a leading automotive tier one supplier to global automotive OEMs, has deployed Dassault ...

MSPL Aims to Increase Mine Productivity with Dassault Systèmes

05/10/2018 4:27PM

Dassault Systèmes today announced at the GEOVIA User Conference in Kolkata that MSPL Limited, a flagship company of the Baldota Group of Companies and a leading iron ore mining, processing and export company with over ...


Similar News

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer

20/10/2018 12:20PM

– In Patients with Brain Metastases at Baseline, ALUNBRIG Reduced the Risk of Progression in the Brain or Death by 73 Percent – – Intracranial Efficacy Data Reinforces Superiority of ALUNBRIG Versus ...